Vmd-102

Preclinical

VVM Discovery, Inc.

Vmd-102 is one of 15 therapeutic programs targeting Hepatocellular Carcinoma (HCC). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Hepatocellular Carcinoma (HCC)Recruiting

Hepatocellular Carcinoma (HCC)Preclinical

Recruiting

Competition

Competitive Landscape

17 competitors in Hepatocellular Carcinoma (HCC)

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 2

3 2

Yervoy

Bristol-Myers Squibb

Phase 2

2 3

Tecentriq

Roche

Phase 2

2 4

Imfinzi

AstraZeneca

Phase 2

1 5

Opdivo

Bristol-Myers Squibb

Phase 2

1 6

Farxiga

AstraZeneca

Phase 2

1 7

Beyfortus

BeiGene

Phase 2

1 8

Zofran

Novartis

Phase 2

1 9

Nitrostat

VViatris Specialty LLC

Phase 2

1 10

Actemra

CCelltrion

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

PreclinicalRecruiting

Hepatocellular Carcinoma (HCC)

NCT07636785

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma (HCC)1 trial

A Phase 1 and 2 First-in-human, Open-label, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of VMD-102 in Participants With Hepatocellular Carcinoma and Other Advanced Solid Tumors

Recruiting·VVM Discovery, Inc.·Preclinical·NCT07636785·111 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vmd-102. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Vmd-102. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — VM Discovery, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: VVM Discovery, Inc.

Vmd-102

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Hepatocellular Carcinoma (HCC)1 trial

References

Drug Info

Quick Facts

Related News